tiprankstipranks
Connect Biopharma Triumphs with Rademikibart Trials
Company Announcements

Connect Biopharma Triumphs with Rademikibart Trials

Connect Biopharma Holdings Ltd. (CNTB) has released an update.

Don't Miss our Black Friday Offers:

Connect Biopharma Holdings Ltd. has reported a successful 2023 with two positive trial readouts for their lead drug, rademikibart, showing promise in treating asthma and atopic dermatitis. The company is preparing for pivotal meetings with the FDA in Q2 2024 and has secured an exclusive licensing agreement with Simcere for the drug’s commercialization in Greater China. Furthermore, with a strong financial position, Connect Biopharma anticipates its current cash reserves will fund operations well into 2026.

For further insights into CNTB stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskConnect Biopharma Welcomes New Finance VP
TipRanks Auto-Generated NewsdeskConnect Biopharma Pivots to U.S. Market Strategy
TheFlyConnect Biopharma reports 1H net income $7.6M vs. net loss ($30.5M) 1H last year
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App